HealthMyne CEO Rose Higgins Featured in Applied Clinical Trials

December 9, 2020 | Article

Pharmaceutical industry media publication Applied Clinical Trials recently published a guest column from HealthMyne CEO Rose Higgins that explains the benefits that radiomics deliver for clinical trials.

In the column, Higgins provides a quick background summary on the field of radiomics, and describes three essential ways that the technology helps life sciences companies advance clinical trial performance, including:

  • Accelerated development of therapies
  • Greater personalization of treatment
  • Discovery of new biomarkers

“Radiomics unleashes powerful insights about the characteristics and progress of lesions and tumors that are not discernible from traditional reading methods of imaging modalities such as CT, MRI, or PET scans so life sciences organizations can leverage them in new ways,” Higgins writes.

Click below to learn more about how life science companies can use radiomics to improve clinical trials.